The U.S. Food and Drug Administration authorized the marketing of 24 more nicotine pouch products on October 30. All are Velo, made by Modoral Brands, and all are listed at 4 mg of nicotine. The agency said the total number of nicotine pouches it has cleared now stands at 67.
Two days later, Pediatrics published an analysis of why American adolescents use the products at all. The two documents answer different questions and do not contradict each other. Read together, they describe a category whose commercial case and whose youth risk run through the same features — flavor, convenience, and a pouch that sits between lip and gum without anyone noticing.
What the agency approved, and the sentence attached to it
The order covers eight Velo product names in four flavors — among them lime, orange crema, passion fruit and cinnamon — multiplied by three packaging types, for 24 unique products. All three variants use certified child-resistant packaging, which the FDA has urged on manufacturers to reduce accidental poisoning in young children; the applications went through the agency’s nicotine pouch pilot program, built to shorten reviews.
Under the premarket tobacco product pathway, the test is whether a product’s public health benefits outweigh its risks to the population as a whole. The FDA said the newly authorized products contain lower levels of harmful and potentially harmful constituents than cigarettes and smokeless tobacco, “many of which were too low to be quantified,” and no measurable levels of several carcinogenic constituents, including some linked to oral cancer in smokeless tobacco users.
The benefit is also conditional, as the agency said in the same paragraph: the gain applies to adults 21 and older who currently smoke and who switch completely. “Dual use does not provide the same degree of health benefit.”
It was not the regulator’s first endorsement of the category. On June 30 the FDA issued modified risk granted orders for 20 ZYN products, permitting the claim that “using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” Those orders expire in five years, and the agency said it may withdraw them if marketing stops benefiting the population as a whole — “such as if there is a significant increase in youth uptake.” The same announcement carries the qualifier that sits underneath the whole category: there is no safe tobacco product, and those who do not use tobacco products should not start.
Two days later, a different kind of document
The Pediatrics study draws on Monitoring the Future, the annual nationally representative survey of U.S. eighth, tenth and twelfth graders. In the 2025 wave, 23,726 students took part; a randomly assigned third received the module with nicotine pouch questions, and 484 of them — 6.1% — reported having ever used a pouch. Of those, 40.4% had used one in the past 30 days, a mean of 9.1 days.
Asked to pick their reasons from a list of ten, the ever-users answered in this order: experimentation (32.3%), nicotine buzz (30.5%), relaxation (22.7%), appealing flavors (17.4%), convenience (16.5%), socializing (16.0%), boredom (11.7%), ability to conceal use (11.0%), to quit smoking (6.2%), and feeling addicted (2.1%). This is a cross-sectional survey of self-reported check-boxes, not a study of causes, and the authors say so — the list was predefined and the items have not been cognitively tested, so “convenience,” for instance, may mean easy to use, easy to buy, or easy to hide.
Which reasons track with heavier use
The more interesting result is what happens when each reason is set against use in the past 30 days and against how many days out of 30. Three reasons were associated with both: appealing flavors (prevalence ratio 1.50, 95% CI 1.10–2.04; incidence rate ratio 1.60, 1.17–2.20), convenience (2.09, 1.69–2.58; 1.63, 1.19–2.24) and feeling addicted (2.35, 1.92–2.87; 2.55, 1.79–3.62). Four more were associated with past-30-day use but not with frequency — nicotine buzz, relaxation, socializing, and concealment — while experimentation ran the other way, associated with less frequent use (0.42, and the estimate is compatible with a wide range).
The estimate for “feeling addicted” deserves caution: barely 2% endorsed it, so its interval rests on very few people, and the authors flag underreporting as one explanation. The broader pattern is what they emphasise. Flavors may blunt nicotine’s bitterness and irritation, and products that are easy to use may encourage escalation, particularly where vaping is not possible. Their recommendation is a reframing — treat convenience as a risk factor rather than a neutral product feature — and they note that the reasons adolescents give for pouches overlap heavily with those they give for e-cigarettes, which suggests the prevention playbook built for vaping may transfer.
How common pouch use actually is
The picture from federal surveillance is smaller and less alarming than a headline about “rising youth use” would suggest — and more complicated than a reassurance would.
The FDA’s read of the 2025 National Youth Tobacco Survey, released in June, found about 2 million middle and high school students, or 7.2%, reporting current use of any tobacco product. E-cigarettes remained the most common category at 5.2%, nicotine pouches were second at 1.7%, and cigarettes third at 1.4%. The agency described pouch use as low overall and stable between 2024 and 2025, even as it acknowledged that high school use had increased across 2022 to 2025. CDC’s figures for 2024 put current pouch use at 1.0% of middle schoolers and 2.4% of high schoolers — and among those current users, 86.1% of high schoolers and 85.4% of middle schoolers had used a flavored pouch.
On the adult side, CDC reports that 2.9% of U.S. adults had ever used a pouch in 2022 and 0.4% were current users, with use most often reported by adults who currently smoke, followed by those who formerly smoked. Sales data it cites run from 126 million pouches in August 2019 to 808 million in March 2022; pouches at 6 mg or less were the most commonly sold, while 8 mg products grew fastest.
The adult case rests on switching, and one trial tested the flavor question
For adults, the public-health argument in the FDA’s orders is substitution. The randomized evidence on it is thinner than the marketing implies; one trial published in Drug and Alcohol Dependence in October tested a specific part — whether flavors matter.
The study randomized 402 adults who smoked at least five cigarettes a day and wanted to replace them with pouches, across three groups: immediate access to seven pouch flavors, unflavored-only access for six weeks, or unflavored for three weeks followed by flavor access. At week six, the flavor and unflavored groups did not differ on the primary outcome of a 50% or greater drop in expired-air carbon monoxide (14.3% versus 14.2%), nor on mean carbon monoxide (18.3 versus 16.5 ppm), cigarette reduction (50.3% versus 51.6%) or carbon-monoxide-verified seven-day abstinence (9.3% versus 8.9%). Access to pouches reduced smoking either way. Flavor did increase smoke-free days early on, with the effect fading, and among participants who had not responded by week three, later flavor access improved cigarette reduction (33.3% versus 18.6%).
It is worth naming who ran it. The first author and several co-authors are employed by or consult for Altria Client Services, the company behind the brand tested, and the disclosed interests include funding from Altria, Philip Morris International, Swedish Match, Juul Labs and others. That does not make the result wrong; it does mean the trial should be read as industry-run evidence on industry products, and single-trial evidence at that, over six weeks, in people who had already decided they wanted to switch.
What the cessation guidance says
CDC is direct on the question the marketing invites: the FDA has not approved any nicotine pouch to help people quit smoking, and more research is needed before the potential effects on quitting are understood. Seven medications are approved for that purpose, and combining medication with behavioral counselling can more than double a person’s chances of quitting for good. The agency also lists the developmental concerns plainly: nicotine is toxic to developing fetuses, can harm brain development up to about age 25, and adolescents can show signs of dependence quickly, even without daily use.
What we did not find
No long-term health-outcome data on pouches. CDC says scientists are still learning about short- and long-term effects, and the products have only been on the U.S. market since 2016. No trial in which pouches were tested as a cessation aid with abstinence outcomes past a few months. No study establishing that flavors are the only or main driver of youth use — the Pediatrics paper shows association, in one survey year, not causation. And nothing in the documents reviewed here supports the cognitive or productivity claims that circulate around nicotine in adult wellness circles.
If you smoke and want to stop, the route with evidence behind it is an approved medication plus counselling, and that is a conversation to have with a healthcare professional rather than a product to buy. Nothing here is medical advice; our medical disclaimer sets out the limits, and our earlier look at cannabis marketed as a sleep aid applied the same test to a different aisle.